|
DK1202736T3
(da)
*
|
1999-07-28 |
2008-12-15 |
Univ Leland Stanford Junior |
Nikotin i terapeutisk angiogenese og vasculogenese
|
|
US8914114B2
(en)
|
2000-05-23 |
2014-12-16 |
The Feinstein Institute For Medical Research |
Inhibition of inflammatory cytokine production by cholinergic agonists and vagus nerve stimulation
|
|
US6492385B2
(en)
|
2000-08-18 |
2002-12-10 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
WO2002016358A2
(en)
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
|
WO2002016357A2
(en)
|
2000-08-18 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted aryl moieties for treatment of disease (nicotinic acetylcholine receptor ligands)
|
|
US6599916B2
(en)
|
2000-08-21 |
2003-07-29 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease
|
|
WO2002017358A2
(en)
|
2000-08-21 |
2002-02-28 |
Pharmacia & Upjohn Company |
Quinuclidine-substituted heteroaryl moieties for treatment of disease (nicotinic acetylcholine receptor antagonists)
|
|
US20050130990A1
(en)
*
|
2001-03-23 |
2005-06-16 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
CA2341952A1
(en)
*
|
2001-03-23 |
2002-09-23 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory pulmonary diseases
|
|
PE20021019A1
(es)
|
2001-04-19 |
2002-11-13 |
Upjohn Co |
Grupos azabiciclicos sustituidos
|
|
AR036041A1
(es)
*
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos aromaticos heterociclicos sustituidos con quinuclidina y composiciones farmaceuticas que los contienen
|
|
AR036040A1
(es)
|
2001-06-12 |
2004-08-04 |
Upjohn Co |
Compuestos de heteroarilo multiciclicos sustituidos con quinuclidinas y composiciones farmaceuticas que los contienen
|
|
WO2003018585A1
(en)
|
2001-08-24 |
2003-03-06 |
Pharmacia & Upjohn Company |
Substituted-heteroaryl-7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
|
US20030069296A1
(en)
*
|
2001-08-24 |
2003-04-10 |
Wishka Donn G. |
Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease
|
|
DE60218493D1
(de)
*
|
2001-09-12 |
2007-04-12 |
Pharmacia & Upjohn Co Llc |
Substituierte 7-aza-ä2.2.1übicycloheptane für die behandlung von krankheiten
|
|
KR100614900B1
(ko)
|
2001-10-02 |
2006-08-25 |
파마시아 앤드 업존 캄파니 엘엘씨 |
질병의 치료를 위한 아자비시클릭-치환된 융합-헤테로아릴화합물
|
|
CA2466375A1
(en)
*
|
2001-11-08 |
2003-05-15 |
Pharmacia & Upjohn Company |
Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
|
|
EP1442037A1
(en)
|
2001-11-09 |
2004-08-04 |
PHARMACIA & UPJOHN COMPANY |
Azabicyclic-phenyl-fused-heterocyclic compounds and their use as alpha7 nachr ligands
|
|
BR0214929A
(pt)
*
|
2001-12-14 |
2006-05-30 |
Targacept Inc |
métodos e composições para o tratamento de distúrbios do sistema nervoso central
|
|
DE10164139A1
(de)
|
2001-12-27 |
2003-07-10 |
Bayer Ag |
2-Heteroarylcarbonsäureamide
|
|
US6852741B2
(en)
|
2001-12-31 |
2005-02-08 |
University Of Florida |
Compositions and methods for treatment of neurological disorders
|
|
AU2003210730A1
(en)
|
2002-02-15 |
2003-09-09 |
Pharmacia And Upjohn Company |
Azabicyclo-substituted benzoylamides and thioamides for treatment of cns-related disorders
|
|
US6858613B2
(en)
*
|
2002-02-19 |
2005-02-22 |
Pfizer Inc. |
Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
|
|
CA2476624A1
(en)
*
|
2002-02-19 |
2003-08-28 |
Pharmacia & Upjohn Company |
Azabicyclic compounds for the treatment of disease
|
|
BR0307874A
(pt)
*
|
2002-02-20 |
2004-12-28 |
Upjohn Co |
Atividade de compostos azabicìclicos com receptor de acetilcolina nicotìnica alfa7
|
|
US8039459B2
(en)
|
2004-07-15 |
2011-10-18 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
US8557804B2
(en)
|
2002-03-25 |
2013-10-15 |
Universite Laval |
Nicotinic receptor agonists for the treatment of inflammatory diseases
|
|
EP1542999A1
(en)
*
|
2002-08-01 |
2005-06-22 |
Pharmacia & Upjohn Company LLC |
1h-pyrazole and 1h-pyrrole-azabicyclic compounds with alfa-7 nachr activity
|
|
CA2495248A1
(en)
*
|
2002-08-30 |
2004-03-11 |
Memory Pharmaceuticals Corporation |
Anabaseine derivatives useful in the treatment of neurodegenerative diseases
|
|
WO2004039815A2
(en)
*
|
2002-11-01 |
2004-05-13 |
Pharmacia & Upjohn Company Llc |
Compounds having both alpha7 nachr agonist and 5ht antagonist activity for treatment of cns diseases
|
|
DE10251963A1
(de)
|
2002-11-08 |
2004-05-19 |
Lts Lohmann Therapie-Systeme Ag |
Transmucosale pharmazeutische Darreichungsform
|
|
DE60317564T2
(de)
*
|
2002-12-06 |
2008-10-23 |
The Feinstein Institute For Medical Research |
Hemmung von entzündungen unter verwendung von alpha-7-rezeptor verbindenden cholinergen agonisten
|
|
US7238715B2
(en)
*
|
2002-12-06 |
2007-07-03 |
The Feinstein Institute For Medical Research |
Treatment of pancreatitis using alpha 7 receptor-binding cholinergic agonists
|
|
WO2005023942A2
(en)
*
|
2003-02-20 |
2005-03-17 |
University Of Florida |
Materials and methods for inhibiting fouling of surfaces exposed to aquatic environments
|
|
US8580842B2
(en)
*
|
2003-09-30 |
2013-11-12 |
Abbott Gmbh & Co. Kg |
Heteroaryl-substituted 1,3-dihydroindol-2-one derivatives and medicaments containing them
|
|
WO2005092308A2
(en)
*
|
2004-03-25 |
2005-10-06 |
The Feinstein Institute For Medical Research |
Neural tourniquet
|
|
US10912712B2
(en)
|
2004-03-25 |
2021-02-09 |
The Feinstein Institutes For Medical Research |
Treatment of bleeding by non-invasive stimulation
|
|
WO2005123075A2
(en)
*
|
2004-06-08 |
2005-12-29 |
University Of Florida Research Foundation, Inc. |
Controlling angiogenesis with anabaseine analogs
|
|
CN101124012B
(zh)
|
2004-12-27 |
2012-09-05 |
范因斯坦医学研究院 |
通过电刺激迷走神经治疗炎症性疾病的装置
|
|
US11207518B2
(en)
|
2004-12-27 |
2021-12-28 |
The Feinstein Institutes For Medical Research |
Treating inflammatory disorders by stimulation of the cholinergic anti-inflammatory pathway
|
|
CA2610795C
(en)
*
|
2005-06-07 |
2015-01-06 |
University Of Florida Research Foundation, Inc. |
3-arylidene-anabaseine compounds as alpha 7 nicotitnic receptor selective ligands
|
|
US8316104B2
(en)
|
2005-11-15 |
2012-11-20 |
California Institute Of Technology |
Method and apparatus for collaborative system
|
|
US7662965B2
(en)
|
2006-01-26 |
2010-02-16 |
Cornerstone Therapeutics, Inc. |
Anabaseine derivatives, pharmaceutical compositions and method of use thereof
|
|
US20080167286A1
(en)
|
2006-12-12 |
2008-07-10 |
Abbott Laboratories |
Pharmaceutical compositions and their methods of use
|
|
US8486979B2
(en)
*
|
2006-12-12 |
2013-07-16 |
Abbvie Inc. |
1,2,4 oxadiazole compounds and methods of use thereof
|
|
UY30846A1
(es)
*
|
2006-12-30 |
2008-07-31 |
Abbott Gmbh & Amp |
Derivados de oxindol sustituidos, medicamentos que los comprenden y uso de los mismos
|
|
SA08290475B1
(ar)
*
|
2007-08-02 |
2013-06-22 |
Targacept Inc |
(2s، 3r)-n-(2-((3-بيردينيل)ميثيل)-1-آزا بيسيكلو[2، 2، 2]أوكت-3-يل)بنزو فيوران-2-كربوكساميد، وصور أملاحه الجديدة وطرق استخدامه
|
|
US8391970B2
(en)
|
2007-08-27 |
2013-03-05 |
The Feinstein Institute For Medical Research |
Devices and methods for inhibiting granulocyte activation by neural stimulation
|
|
CA2707671C
(en)
*
|
2007-12-07 |
2016-02-02 |
Abbott Gmbh & Co. Kg |
5,6-disubstituted oxindole-derivatives and use thereof for treating vasopressine-dependent diseases
|
|
JP5595926B2
(ja)
*
|
2007-12-07 |
2014-09-24 |
アボット ゲーエムベーハー ウント カンパニー カーゲー |
５−ハロゲン−置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
|
|
WO2010009775A1
(de)
*
|
2007-12-07 |
2010-01-28 |
Abbott Gmbh & Co. Kg |
Carbamat-substituierte oxindol-derivate und ihre verwendung zur behandlung von vasopressin-abhängigen erkrankungen
|
|
JP5701607B2
(ja)
*
|
2007-12-07 |
2015-04-15 |
アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー |
アミドメチル置換オキシインドール誘導体およびバソプレッシン依存性疾患の治療へのこれらの使用
|
|
US8383657B2
(en)
|
2007-12-21 |
2013-02-26 |
Abbott Laboratories |
Thiazolylidine urea and amide derivatives and methods of use thereof
|
|
US9662490B2
(en)
|
2008-03-31 |
2017-05-30 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation and administration of an anti-inflammatory drug
|
|
WO2009146030A1
(en)
|
2008-03-31 |
2009-12-03 |
The Feinstein Institute For Medical Research |
Methods and systems for reducing inflammation by neuromodulation of t-cell activity
|
|
JP2011516489A
(ja)
*
|
2008-03-31 |
2011-05-26 |
ユニバーシティ・オブ・サウス・フロリダ |
疾患誘発性運動失調症および非運動失調性平衡異常の治療法
|
|
ES2452484T3
(es)
|
2008-11-18 |
2014-04-01 |
Setpoint Medical Corporation |
Dispositivos para optimizar la colocación de electrodos para la estimulación antiinflamatoria
|
|
HUE037938T2
(hu)
|
2008-11-19 |
2018-09-28 |
Forum Pharmaceuticals Inc |
Skizofrénia negatív tüneteinek kezelése (R)-7-klór-N-(kinuklidin-3-il)benzo[b]tiofén-2-karboxamiddal és ennek gyógyszerészetileg elfogadható sójával
|
|
TW201031664A
(en)
|
2009-01-26 |
2010-09-01 |
Targacept Inc |
Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
|
|
US9211410B2
(en)
|
2009-05-01 |
2015-12-15 |
Setpoint Medical Corporation |
Extremely low duty-cycle activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
US8996116B2
(en)
|
2009-10-30 |
2015-03-31 |
Setpoint Medical Corporation |
Modulation of the cholinergic anti-inflammatory pathway to treat pain or addiction
|
|
US8788034B2
(en)
|
2011-05-09 |
2014-07-22 |
Setpoint Medical Corporation |
Single-pulse activation of the cholinergic anti-inflammatory pathway to treat chronic inflammation
|
|
JP5808319B2
(ja)
*
|
2009-05-11 |
2015-11-10 |
フォルム ファーマシューティカルズ、インコーポレイテッド |
アセチルコリンエステラーゼ阻害剤と組み合わせた特定のα７ニコチン酸受容体を用いた認知障害の治療
|
|
EP2435080A2
(en)
|
2009-05-29 |
2012-04-04 |
Abbott Laboratories |
Pharmaceutical compositions for the treatment of pain
|
|
EP2440284B1
(en)
|
2009-06-09 |
2018-09-12 |
Setpoint Medical Corporation |
Nerve cuff with pocket for leadless stimulator
|
|
WO2014169145A1
(en)
|
2013-04-10 |
2014-10-16 |
Setpoint Medical Corporation |
Closed-loop vagus nerve stimulation
|
|
US9833621B2
(en)
|
2011-09-23 |
2017-12-05 |
Setpoint Medical Corporation |
Modulation of sirtuins by vagus nerve stimulation
|
|
EP2515996B1
(en)
|
2009-12-23 |
2019-09-18 |
Setpoint Medical Corporation |
Neural stimulation devices and systems for treatment of chronic inflammation
|
|
ES2570657T3
(es)
|
2010-05-17 |
2016-05-19 |
Forum Pharmaceuticals Inc |
Una forma cristalina de hidrocloruro de (R)-7-cloro-n-(quinuclidin-3-il)benzo[b]tiofeno-2-carboxamida monohidrato
|
|
WO2012031220A2
(en)
|
2010-09-03 |
2012-03-08 |
University Of Florida Research Foundation, Inc. |
Nicotine compounds and analogs thereof, synthetic methods of making compounds, and methods of use
|
|
US12172017B2
(en)
|
2011-05-09 |
2024-12-24 |
Setpoint Medical Corporation |
Vagus nerve stimulation to treat neurodegenerative disorders
|
|
US9572983B2
(en)
|
2012-03-26 |
2017-02-21 |
Setpoint Medical Corporation |
Devices and methods for modulation of bone erosion
|
|
WO2013169646A1
(en)
|
2012-05-08 |
2013-11-14 |
Envivo Pharmaceuticals, Inc. |
Methods of maintaining, treating or improving cognitive function
|
|
US11311725B2
(en)
|
2014-10-24 |
2022-04-26 |
Setpoint Medical Corporation |
Systems and methods for stimulating and/or monitoring loci in the brain to treat inflammation and to enhance vagus nerve stimulation
|
|
US11406833B2
(en)
|
2015-02-03 |
2022-08-09 |
Setpoint Medical Corporation |
Apparatus and method for reminding, prompting, or alerting a patient with an implanted stimulator
|
|
US10596367B2
(en)
|
2016-01-13 |
2020-03-24 |
Setpoint Medical Corporation |
Systems and methods for establishing a nerve block
|
|
US10695569B2
(en)
|
2016-01-20 |
2020-06-30 |
Setpoint Medical Corporation |
Control of vagal stimulation
|
|
EP3405255B1
(en)
|
2016-01-20 |
2025-12-31 |
Setpoint Medical Corporation |
IMPLANTABLE MICROSTIMULATORS AND INDUCTION CHARGING SYSTEMS
|
|
US11471681B2
(en)
|
2016-01-20 |
2022-10-18 |
Setpoint Medical Corporation |
Batteryless implantable microstimulators
|
|
US10583304B2
(en)
|
2016-01-25 |
2020-03-10 |
Setpoint Medical Corporation |
Implantable neurostimulator having power control and thermal regulation and methods of use
|
|
US11096932B2
(en)
|
2016-09-29 |
2021-08-24 |
The Uab Research Foundation |
Methods and compositions for increasing mucus clearance
|
|
US11173307B2
(en)
|
2017-08-14 |
2021-11-16 |
Setpoint Medical Corporation |
Vagus nerve stimulation pre-screening test
|
|
US11660443B2
(en)
|
2018-04-20 |
2023-05-30 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via electrical trigeminal nerve stimulation
|
|
US20210255202A1
(en)
|
2018-06-13 |
2021-08-19 |
Michael R. D'Andrea |
Methods and dosing regimens for preventing or delaying onset of alzheimer's disease and other forms of dementia and mild congnitive impairment
|
|
US11260229B2
(en)
|
2018-09-25 |
2022-03-01 |
The Feinstein Institutes For Medical Research |
Methods and apparatuses for reducing bleeding via coordinated trigeminal and vagal nerve stimulation
|
|
CN113939334A
(zh)
|
2019-04-12 |
2022-01-14 |
赛博恩特医疗器械公司 |
迷走神经刺激来处理神经退行性障碍
|
|
IL298193B2
(en)
|
2020-05-21 |
2024-01-01 |
Feinstein Institutes For Medical Research |
Systems and methods for vagus nerve stimulation
|
|
GB2612481A
(en)
*
|
2020-06-09 |
2023-05-03 |
Fadly Abd El Ghany Elkazaz Mohamed |
A novel medicament for immune modulation and treating chronic or hyper inflammation
|
|
WO2022245878A1
(en)
|
2021-05-17 |
2022-11-24 |
Setpoint Medical Corporation |
Neurostimulation parameter authentication and expiration system for neurostimulation
|